CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 27, 2012
Result type: Reports
Project Number: SF0295-000
Product Line: Reimbursement Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Therapeutic Area: Deep-vein thrombosis without symptomatic pulmonary embolism

Indications: Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism

Submission Type: Request For Advice

Project Status: Complete